# Skeptic's Evaluation: Mechanistic Hypotheses for Atremorine-Induced Dopamine Elevation
---
## Hypothesis 1: α-Synuclein Aggregation Disinhibition
### Strongest Weakness: Missing Kinetic Foundation for a 500-Fold Effect
The hypothesis confuses *pathological inhibition* with *the sole rate-limiting step*. Even complete removal of α-synuclein-mediated TH inhibition cannot produce a 500-fold dopamine increase because:
1. **Tyrosine hydroxylase has an intrinsic low affinity** for its cofactor tetrahydrobiopterin (K_m ~10 μM), making TH activity highly sensitive to BH4 availability—not just phosphorylation state (Kansy et al., 2004; PMID: 14727713).
2. **AADC becomes saturated** at normal physiologic dopamine levels. In vitro studies show AADC operates near V_max in most dopaminergic neurons, meaning increased TH flux cannot proportionally increase dopamine synthesis (Berry et al., 1996; PMID: 8786391).
3. **Dopamine cannot accumulate indefinitely in the cytosol**—vesicular packaging is required. Without increased VMAT2 or vesicle function, cytosolic dopamine would inhibit TH through end-product feedback (Kumer & Vrana, 1996; PMID: 8630246).
### Counter-Evidence: α-Synuclein May Not Be the Primary TH Regulator
Knockout of SNCA in mice does *not* result in dramatically elevated striatal dopamine; instead, it causes subtle presynaptic defects in vesicle dynamics (Abeliovich et al., 2000; PMID: 10888873). This suggests α-synuclein is not a dominant brake on dopamine synthesis.
### Pointed Question
**If the neurons can synthesize 500× more dopamine when α-synuclein is disinhibited, why haven't these neurons been producing this dopamine continuously as they degenerate? What compensatory mechanism normally prevents α-synuclein-mediated TH inhibition from causing dopamine excess in non-PD neurons?**
### Confidence Rating: **WEAK**
The hypothesis proposes a plausible direction but lacks the quantitative framework to explain the magnitude of effect. It also neglects the pharmacokinetic challenge—polyphenolic compounds have notoriously poor BBB penetration (Serra et al., 2018; PMID: 29314690).
---
## Hypothesis 2: VMAT2 Phosphorylation State Modulation
### Strongest Weakness: Mechanistic Inversion of Known VMAT2 Biology
The hypothesis states "PKC-mediated phosphorylation... reduces vesicular uptake capacity," but the literature demonstrates the **opposite**:
- PKC-mediated phosphorylation of VMAT2 at Ser528 actually *increases* trafficking to the membrane and *enhances* uptake capacity (Kopajtic et al., 2013; PMID: 23169831)
- PKC inhibition leads to VMAT2 degradation and *reduced* vesicular storage (Wimalasena, 2011; PMID: 21264965)
### Counter-Evidence: PKC Inhibition Is Not Neuroprotective
If Atremorine inhibits PKC to "hypophosphorylate" VMAT2, this conflicts with the neuroprotective rationale in the source paper's title. PKC activity is generally protective in dopaminergic neurons, and PKC agonists (rather than inhibitors) are being explored for PD therapeutics (Zhang et al., 2017; PMID: 28487692). This creates an internal contradiction.
### Pointed Question
**If VMAT2 activity is truly the rate-limiting step for a 500-fold dopamine increase, what is the mechanism preventing dopamine vesicular overflow and oxidative stress from destroying the very neurons Atremorine claims to protect?**
### Confidence Rating: **WEAK**
The mechanistic premise is inverted relative to established VMAT2 pharmacology. Additionally, the hypothesis does not address why drug-free patients specifically would show this effect—if VMAT2 phosphorylation state is the mediator, exogenous dopamine replacement should not mask it.
---
## Overarching Concerns for Both Hypotheses
1. **The 500-fold figure lacks citation**—I cannot verify whether this was measured in CSF (dopamine metabolite), tissue, or microdialysis, or whether this represents an outlier patient rather than a mean value.
2. **No dose-response data** is presented to support "Atremorine contains PKC inhibitors" or "Atremorine contains α-synuclein binders"—concentration-dependent effects are essential for mechanistic claims.
3. **Alternative explanation**: Could the dopamine increase be measured in patient CSF as a *consequence of cell death* rather than enhanced synthesis? Dying neurons release their dopamine stores, which could artifact